TMEM97 and neoplasm: Using specific ligands that can discriminate between SR-BP and sigma2, sigma2 receptors were found to be overexpressed in tumour cells as compared with their normal counterparts, including breast, neural, lung, prostate and melanoma tumours (Vilner et al, 1995).